A growing list of industry leaders including Chiesi, Moderna, and Merck Animal Health are using Agentforce Life Sciences to scale AI-native clinical and commercial operations.
The majority of the top global pharmaceutical companies rely on Salesforce, with many now expanding to adopt Agentforce Life Sciences for Customer Engagement.
Customers are going live in as little as five weeks, proving the Platform’s speed to value and ease of deployment, despite having launched just seven months ago and in sharp contrast with legacy alternatives that have been in the market for years.
SAN FRANCISCO — May 19, 2026 — The healthcare industry is at a critical juncture where the technology supporting it is lagging far behind the speed of medical innovation, a gap the industry can no longer afford. Fragmented insights from vast amounts of unused data, coupled with field representatives spending up to 70% of their time on admin tasks, create urgent operational headwinds. While leaders view AI agents as a solution, the highly regulated nature of life sciences requires uncompromising integrity and trust, making it essential to choose a mature, proven platform built for the future.
That’s why leading pharmaceutical, clinical research, biotechnology, and medical device companies have chosen the Salesforce Agentforce 360 Platform to transform the way they engage with patients and bring therapies and devices to market. Building on Salesforce’s nearly three decades as the world’s #1 AI CRM, Agentforce Life Sciences provides the tailored data foundation, AI models, and intelligence for every team and function across the enterprise — and Agentforce Life Sciences for Customer Engagement delivers the specialized tools commercial teams need to drive meaningful HCP interactions.
